Short answer
Insulet Corporation (PODD) filed its Q2 2025 10-Q quarterly report on Aug 7, 2025 for the quarter ended Jun 30, 2025. Quarterly revenue was $649M (up 32.9% year over year) with net income of $23M.
Q2 2025 key financials · XBRL
- Revenue
- $649M
- +32.9% YoY · +14.1% QoQ
- Net income
- $23M
- −88.1% YoY · −36.4% QoQ
- Operating margin
- 18.7%
- Gross margin
- 69.7%
- EPS (diluted)
- $0.32
- −87.6% YoY · −36.0% QoQ
Source: XBRL data from the Insulet Corporation (PODD) Q2 2025 10-Q on SEC EDGAR. USD.
Insulet Corporation Q2 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No new or changed risk factors since 2024 10-K as stated in 10-Q risk factors section
- Carried-forward regulatory risk includes compliance with FDA medical device regulations and post-market surveillance
- Operational risk from supply chain disruptions impacting product availability and manufacturing timelines
- Competitive risk from evolving diabetes management technologies and alternative insulin delivery systems
- Financial risk related to dependence on key suppliers and potential impacts on liquidity and operating results
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Insulet Corporation quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.